source
- BMS reports Phase 3 success for RYZ101 in GEP-NET trialBristol Myers Squibb said its radiopharmaceutical candidate RYZ101 met the primary endpoint in a late‑stage Phase 3 study. The drug was acquired in BMS's $4.1 billion purchase of RayzeBio, complete…
- Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefitMirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage s…